drugset / Trial / NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Timeline
- Start
- 2025-02-27
- Primary completion
- 2028-04
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | — | Intravenous |